Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aimed at easing knee pain fails to finish trial

NCT ID NCT05838742

Symptom relief Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called GSK3858279 in 314 adults with moderate to severe knee osteoarthritis pain. The goal was to find the best dose that reduces pain safely. However, the trial was stopped early, so we have less information than planned.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GSK3858279
What this could lead to
If successful, this could point toward a new non-opioid pain reliever for people with knee osteoarthritis.
What could go wrong
The study was terminated early, so results are limited. It is still in Phase 2, meaning it is not yet proven safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

314 people

The number who actually took part.

Started

Sep 2023

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be 40 to 80 years of age inclusive * OA of the index knee as defined by symptomatic for ≥ 6 months with a clinical diagnosis of OA as per American College of Rheumatology (ACR) clinical diagnosis criteria. * Kellgren and Lawrence (KL) score ≥ 2 on X-ray in the index knee * An average of the average daily pain score of ≥4 and less than or equal to (≤) 9 by the 11-point NRS (0-10) * Body mass index (BMI) of \< 40 kilogram per meter square (kg/m\^2) (inclusive). * Capable of giving signed informed consent. Exclusion Criteria: * History or presence of cardiovascular, renal, gastrointestinal, lymphatic disorders which in the opinion of the investigator would interfere with the study procedures and/or assessments. * History or current evidence of any inflammatory arthritis such as rheumatoid arthritis, infective arthritis, Paget's disease, osteonecrosis, osteoporotic fracture, or any other joint disease that in the Investigator's opinion would interfere with the assessment of pain and other symptoms of osteoarthritis. * History of significant trauma or surgery to a knee or hip within the last 6 months. * Current immunodeficiency diseases including but not limited to acquired immunodeficiency disorder or immunoglobulin deficiency. * Current or previous active Mycobacterium tuberculosis * History or evidence of clinically significant multiple or severe drug allergies * History of malignancy within the last 5 years, except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years. * Alanine transaminase (ALT) \>1.5 times upper limit of normal (ULN). * Bilirubin \>1.5 times ULN (isolated bilirubin \>1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \< 35 percent (%) * Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) * Evidence of renal insufficiency, indicated by estimated creatinine clearance \< 60 milliliter/ minute (mL/min)/1.73 square meter (m\^2) at screening. * Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis, knee are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

musculoskeletal system disorder osteoarthritis osteoarthritis, knee Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoarthritis, knee Pain

Contacts and locations

Locations

  • GSK Investigational Site

    Cerritos, California, 90703, United States

  • GSK Investigational Site

    Huntington Beach, California, 92647, United States

  • GSK Investigational Site

    Santa Clara, California, 95054, United States

  • GSK Investigational Site

    Cooper City, Florida, 33024, United States

  • GSK Investigational Site

    Cutler Bay, Florida, 33189, United States

  • GSK Investigational Site

    Miami, Florida, 33173, United States

  • GSK Investigational Site

    Miami, Florida, 33185, United States

  • GSK Investigational Site

    Wichita, Kansas, 67207, United States

  • GSK Investigational Site

    Louisville, Kentucky, 40213, United States

  • GSK Investigational Site

    New Orleans, Louisiana, 70115, United States

  • GSK Investigational Site

    Henderson, Nevada, 89052, United States

  • GSK Investigational Site

    Williamsville, New York, 14221, United States

  • GSK Investigational Site

    Greensboro, North Carolina, 27410, United States

  • GSK Investigational Site

    Duncansville, Pennsylvania, 16635, United States

  • GSK Investigational Site

    Charlottesville, Virginia, 22911, United States

  • GSK Investigational Site

    Buenos Aires, C1128AAF, Argentina

  • GSK Investigational Site

    Buenos Aires-San Isidro, 1643, Argentina

  • GSK Investigational Site

    Ciudad Autonoma Buenos Aires, C1417, Argentina

  • GSK Investigational Site

    Ciudad AutOnoma de Buenos Aire, 1118, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, C1046AAQ, Argentina

  • GSK Investigational Site

    Mar del Plata, B7600FYK, Argentina

  • GSK Investigational Site

    Botany, New South Wales, 2019, Australia

  • GSK Investigational Site

    Kotara, New South Wales, 2289, Australia

  • GSK Investigational Site

    Sydney, New South Wales, 2010, Australia

  • GSK Investigational Site

    Camberwell, Victoria, 3124, Australia

  • GSK Investigational Site

    Victoria, British Columbia, V8V 4A1, Canada

  • GSK Investigational Site

    Brampton, Ontario, L6T 0G1, Canada

  • GSK Investigational Site

    Guelph, Ontario, N1H 1B1, Canada

  • GSK Investigational Site

    Sarnia, Ontario, N7T 4X3, Canada

  • GSK Investigational Site

    Toronto, Ontario, M5T 2S8, Canada

  • GSK Investigational Site

    Toronto, Ontario, M9V 4B4, Canada

  • GSK Investigational Site

    Winchester, Ontario, K0C 2K0, Canada

  • GSK Investigational Site

    Joliette, Quebec, J6E 6A9, Canada

  • GSK Investigational Site

    Sherbrooke, Quebec, J1L 0H8, Canada

  • GSK Investigational Site

    Trois-Rivières, Quebec, G9A 3X2, Canada

  • GSK Investigational Site

    Beijing, 100083, China

  • GSK Investigational Site

    Beijing, 100730, China

  • GSK Investigational Site

    Changchun, 130021, China

  • GSK Investigational Site

    Chengdu, 610041, China

  • GSK Investigational Site

    Guangzhou, 510000, China

  • GSK Investigational Site

    Hohhot, 010017, China

  • GSK Investigational Site

    Nanjing, 210009, China

  • GSK Investigational Site

    Shanghai, 200011, China

  • GSK Investigational Site

    Shanghai, 200040, China

  • GSK Investigational Site

    Shanghai, 200065, China

  • GSK Investigational Site

    Shenyang, 110022, China

  • GSK Investigational Site

    Shijiazhuang, 050051, China

  • GSK Investigational Site

    Tianjin, 300192, China

  • GSK Investigational Site

    Zhuzhou, 412007, China

  • GSK Investigational Site

    Dax, 40107, France

  • GSK Investigational Site

    La Roche-sur-Yon, 85925, France

  • GSK Investigational Site

    La Rochelle, 17019, France

  • GSK Investigational Site

    Montpellier, 34000, France

  • GSK Investigational Site

    Paris, 75012, France

  • GSK Investigational Site

    Berlin, 10117, Germany

  • GSK Investigational Site

    Hamburg, 20095, Germany

  • GSK Investigational Site

    Hamburg, 22415, Germany

  • GSK Investigational Site

    Magdeburg, 39120, Germany

  • GSK Investigational Site

    Fukuoka, 834-0115, Japan

  • GSK Investigational Site

    Ibaraki, 300-1234, Japan

  • GSK Investigational Site

    Ibaraki, 300-1253, Japan

  • GSK Investigational Site

    Nagano, 390-8601, Japan

  • GSK Investigational Site

    Nagano, 395-8505, Japan

  • GSK Investigational Site

    Osaka, 543-0027, Japan

  • GSK Investigational Site

    Saitama, 330-0074, Japan

  • GSK Investigational Site

    Shimane, 693-8501, Japan

  • GSK Investigational Site

    Tokyo, 103-0027, Japan

  • GSK Investigational Site

    Tokyo, 104-0031, Japan

  • GSK Investigational Site

    Tokyo, 113-8431, Japan

  • GSK Investigational Site

    Chihuahua City, 31000, Mexico

  • GSK Investigational Site

    Guadalajara, 44650, Mexico

  • GSK Investigational Site

    Mexicali, 21200, Mexico

  • GSK Investigational Site

    Mérida, CP 97070, Mexico

  • GSK Investigational Site

    Torreón, 27000, Mexico

  • GSK Investigational Site

    Cape Town, 7130, South Africa

  • GSK Investigational Site

    Cape Town, 7405, South Africa

  • GSK Investigational Site

    Gauteng, 1619, South Africa

  • GSK Investigational Site

    Johannesburg, 2113, South Africa

  • GSK Investigational Site

    Stellenbosch, 7600, South Africa

  • GSK Investigational Site

    Seoul, 03080, South Korea

  • GSK Investigational Site

    Seoul, 06973, South Korea

  • GSK Investigational Site

    Seoul, 07441, South Korea

  • GSK Investigational Site

    A Coruña, 15006, Spain

  • GSK Investigational Site

    Barcelona, 08430, Spain

  • GSK Investigational Site

    Barcelona, 08540, Spain

  • GSK Investigational Site

    Madrid, 28046, Spain

  • GSK Investigational Site

    Santander, 39008, Spain

  • GSK Investigational Site

    Santiago de Compostela, 15702, Spain

  • GSK Investigational Site

    Seville, 41014, Spain

  • GSK Investigational Site

    Blackpool, FY2 0JH, United Kingdom

  • GSK Investigational Site

    Cannock, WS11 0BN, United Kingdom

  • GSK Investigational Site

    London, EN5 3DJ, United Kingdom

  • GSK Investigational Site

    Manchester, M13 9NQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.